Advertisement
U.S. markets closed
Advertisement

Ultragenyx Pharmaceutical Inc. (RARE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
40.16+1.31 (+3.37%)
At close: 04:00PM EST
39.25 -0.91 (-2.27%)
After hours: 04:07PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
Previous Close38.85
Open38.80
Bid38.74 x 800
Ask40.15 x 900
Day's Range38.69 - 40.17
52 Week Range31.52 - 54.98
Volume908,647
Avg. Volume964,890
Market Cap3.298B
Beta (5Y Monthly)0.72
PE Ratio (TTM)N/A
EPS (TTM)-8.97
Earnings DateFeb 14, 2024 - Feb 19, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est90.11
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for RARE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Ultragenyx Pharmaceutical Inc.
    Daily – Vickers Top Buyers & Sellers for 10/17/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    Ultragenyx to Participate at Investor Conferences in November

    6th Annual Evercore ISI HealthCONx on November 28 in Miami Piper Sandler 35th Annual Healthcare Conference on November 29 in New York City NOVATO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that management, will participating in two upcoming investor conferences. 6th Annual Evercore ISI Healt

  • GlobeNewswire

    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    NOVATO, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 22,765 restricted stock units of the company’s common stock to eight newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Em

  • GlobeNewswire

    Ultragenyx to Participate in the Jefferies London Healthcare Conference

    NOVATO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will participate in a fireside chat at the upcoming Jefferies London Healthcare Conference on Tuesday, November 14, 2023, at 12:30 p.m. GMT. The live and a